carvedilol controlled-release / Generic mfg. - LARVOL DELTA

Characterization and Crystal Structural Analysis of Novel Carvedilol Adipate and Succinate Ethanol-Solvated Salts. (PubMed, Molecules) - "The two novel ethanol-solvated salts exhibited enhanced solubility and dissolution rates compared with pure carvedilol in phosphate buffer (pH 6.8). Additionally, the morphologies and attachment energies of the two novel compounds and pure CVD were calculated based on their single-crystal structures, revealing a correlation between attachment energy and dissolution rate."

Journal

Hepatoprotective effects of carvedilol and crocin against leflunomide-induced liver injury. (PubMed, Int Immunopharmacol) - "While the coadministration of carvedilol, crocin and their combination with leflunomide significantly decreased the serum levels of AST, ALT, ALP, hepatic MDA, mTOR gene, PI3K gene, TGF-β, and the pathological changes alongside with the significant elevation of serum albumin, total protein, hepatic catalase, and GSH. This study is suggesting several solutions for Leflunomide-induced hepatotoxicity demonstrated by the protective effect of the antihypertensive drug carvedilol, the natural product crocin, and their combination which was demonstrated to be superior to each drug alone."

Journal • Hepatology • Liver Failure • CAT • mTOR • PI3K • TGFB1

The Effect of Surfactant Type and Concentration on Physicochemical Properties of Carvedilol Solid Dispersions Prepared by Wet Milling Method. (PubMed, Iran J Pharm Res) - "According to the results, partial amorphization occurred in wet-milled samples, as confirmed by XRD and DSC analysis. It was concluded that using an appropriate surfactant along with wet-milling method may have been an effective approach for improving the dissolution rate of CA, a poorly soluble compound."

Journal

Cost-Effectiveness of Lisinopril and Carvedilol for Prevention of Trastuzumab-Induced Cardiotoxicity in US Adults with Early-Stage Breast Cancer (ISPOR 2022) - "This study aimed to assess the cost-effectiveness of lisinopril and carvedilol (Coreg CR) in US adults with eBC receiving trastuzumab, compared with no treatment. Conclusions Based on a WTP of $50,000/QALY, lisinopril is a cost-effective prophylaxis against trastuzumab-induced CTX for US eBC patients. The price is a major impact factor for carvedilol’s economic efficiency."

Clinical • HEOR • Breast Cancer • Oncology • Solid Tumor

Cost-Effectiveness of Lisinopril and Carvedilol for Prevention of Trastuzumab-Induced Cardiotoxicity in US Adults with Early-Stage Breast Cancer (ISPOR 2022) - "This study aimed to assess the cost-effectiveness of lisinopril and carvedilol (Coreg CR) in US adults with eBC receiving trastuzumab, compared with no treatment. Conclusions Based on a WTP of $50,000/QALY, lisinopril is a cost-effective prophylaxis against trastuzumab-induced CTX for US eBC patients. The price is a major impact factor for carvedilol’s economic efficiency."

Clinical • HEOR • Breast Cancer • Oncology • Solid Tumor

Vascular Benefits of Adding CarvedilolCR to Type2 Diabetic Patients on ACEI. (clinicaltrials.gov) - P4 | N=14 | Terminated | Sponsor: University at Buffalo | N=60 ➔ 14 | Active, not recruiting ➔ Terminated

Enrollment change • Trial termination • Diabetes • Hypertension • Immunology • Inflammation • Metabolic Disorders • Type 2 Diabetes Mellitus

Beta-blockers for Atherosclerosis Prevention: a Missed Opportunity? (PubMed, Curr Atheroscler Rep) - "Specifically, the newer BBs (metoprolol ER, carvedilol ER, bisoprolol, and nebivolol) are now documented to be metabolically beneficial. Despite this exciting potential, further research is greatly needed to better establish the possible benefits of the most promising BBs as they might work in combination with other better-established atheropreventive agents. Specifically, there is a need for randomized, prospective, cardiovascular outcome trials (CVOTs) in high-risk patients, adding a BB to background LDL-lowering (statins, etc.), TG-lowering (specifically icosapent ethyl, which reduces ASCVD in patients with high TG, although apparently not via TG-lowering), and/or anti-diabetic (sodium glucose transport-2 inhibitors, SGLT2i, and glucagon-like protein-1 receptor agonists, GLP1-RA) treatments, as indicated in a given subject population."

Journal • Review • Atherosclerosis • Atrial Fibrillation • Cardiovascular • Congestive Heart Failure • Diabetes • Dyslipidemia • Heart Failure • Hypertension • Immunology • Inflammation • Metabolic Disorders • Myocardial Infarction • Pulmonary Arterial Hypertension

Carvedilol With Chemotherapy in Second Line Glioblastoma and Response of Circulating Tumor Cells (clinicaltrials.gov) - P1; N=4; Terminated; Sponsor: West Virginia University; Recruiting ➔ Terminated; Due to Covid

Trial termination • Brain Cancer • Glioblastoma • Glioma • Oncology • Solid Tumor • CTCs • MRI

Lisinopril or Coreg CR® in Reducing Side Effects in Women With Breast Cancer Receiving Trastuzumab (clinicaltrials.gov) - P2; N=468; Completed; Sponsor: University of South Florida; Active, not recruiting ➔ Completed

Adverse events • Clinical • Trial completion • Breast Cancer • HER2 Breast Cancer • HER2 Positive Breast Cancer • Oncology • Solid Tumor • HER-2

Lisinopril or Coreg CR® in Reducing Side Effects in Women With Breast Cancer Receiving Trastuzumab (clinicaltrials.gov) - P2; N=468; Active, not recruiting; Sponsor: University of South Florida; Recruiting ➔ Active, not recruiting; Trial primary completion date: Mar 2016 ➔ Jul 2017

Adverse events • Clinical • Enrollment closed • Trial primary completion date • Breast Cancer • HER2 Breast Cancer • HER2 Positive Breast Cancer • Oncology • Solid Tumor • HER-2

Extended-Release Carvedilol in the Treatment of Hypertension: A Double-Blind, Randomized, Placebo-Controlled Trial. (PubMed, Acta Cardiol Sin) - "There were no differences in safety among the three groups. Carvedilol ER, though well tolerated, did not result in a greater reduction in either SBP or DBP compared with placebo."

Clinical • Journal • Hypertension